Investegate announcements from Ultimovacs ASA, Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program
UV1/pembrolizumab results in 30% complete responses plus 30% partial responsesGood safety and tolerability profile supports expanded Phase II combination programData highlighted at ASCO in poster presentation
(1)
Ultimovacs ASA ( Ultimovacs ) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced the publication in
Frontiers in Immunology of its positive long-term Overall Survival (OS) data from the Phase I trial evaluating the Company s universal cancer vaccine, UV1, in combination with checkpoint inhibitor ipilimumab in patients with metastatic malignant melanoma. As published in the journal, in addition to the achievement of the primary endpoints of safety and tolerability, 50% of the patients were still alive at the data cut-off, supporting the combination of the Company s proprietary UV1 vaccine with ipilimumab, a CTLA-4 checkpoint inhibitor and standard-of-care treatment, in this late-stage patient population.
Ultimovacs ASA: Ultimovacs to Discuss ASCO UV1 Phase I Data in Webcast and Investor Meetings
Ultimovacs ASA ( Ultimovacs ) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced that its management team will discuss data from the abstract of a poster presentation at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting at a series of investor events in May, beginning with a live corporate webcast on Thursday May 20, 2021.
The abstract is titled A Phase I Clinical Trial Investigating the Telomerase Vaccine UV1 in Combination with Pembrolizumab in Patients with Advanced Melanoma . It provides an overview of the open-label, single-arm study investigating the safety and tolerability for the combination of Ultimovacs universal cancer vaccine, UV1, with the checkpoint inhibitor pembrolizumab in patients with metastatic malignant melanoma.
Ultimovacs ASA ("Ultimovacs", ticker ULTI) today announced that an abstract on the Company's Phase I trial evaluating its universal cancer vaccine, UV1, in combination with the checkpoint inhibitor